MJardin Group is a specialized professional cannabis management company that provides cultivation solutions, retail advice and operational management on behalf of license-holders. Their Executive Chairman Rishi Gautam discusses their value proposition in the cannabis market and the capital-raising structure in place to become a publicly-listed entity later this calendar year.
MJardin Group, a manager of cannabis cultivation, processing and retail businesses, is pursuing a roughly $200 million pipeline of acquisitions in the space while raising capital from institutional and retail investors, an executive at the company tells Real Money
DENVER--(BUSINESS WIRE)--MJardin Group (“MJardin” or the “Company”), a leader in North American cannabis facility management, today announces that it has engaged Canaccord Genuity Corp., to act as sole bookrunner, together with KES 7 Capital Inc. as co-lead agent (collectively, the “Agents”), to sell, on a best efforts private placement basis, pursuant to applicable prospectus and registration exemptions, subscription receipts of MJardin Group (the "Subscription Receipts") to raise equity capital (the “Offering”) to accelerate the Company’s expanding growth opportunities.
The company has entered into an exclusive turnkey management agreement with MJardin Group, North America’s largest legal cannabis operator, to operate its facilities in Canada, including its new Winnipeg operation.
MJardin Group, North America’s largest turnkey operator of legal cannabis facilities, is pleased to announce the creation of a new company called GrowForce Holdings Inc. (“GrowForce”). The mission of GrowForce is to become one of the premium licensed cannabis producers in Canada and other federally legal markets worldwide. GrowForce completed a private placement financing of its shares, which was offered to all of the securities holders of MJardin.
The legal cannabis industry is a unique prospect for those looking for a potentially lucrative investment opportunity. In 2017, sales in the US state of Colorado reached $1bn in just eight months, a 21 percent increase from the same period in the previous year. According to Statistics Canada, Canadians spent around CAD 5.7bn ($4.5bn) on both medical and non-medical cannabis in 2017, with numbers expected to swell when the latter is legalised in July this year.